Value of pH regulators in the diagnosis, prognosis and treatment of cancer

Seminars in Cancer Biology

Volumn 43, Issue , 2017, Pages 17-34

  Granja, Sara ^a,b   Tavares Valente, Diana ^a,b,c   Queirós, Odília ^b,c   Baltazar, Fátima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

ATPases; Carbonic anhydrases; Monocarboxylate transporters; pH regulators; Sodium hydrogen exchangers

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CARRIER PROTEIN; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER INHIBITOR; PROTEIN INHIBITOR; PROTON; PROTON PUMP; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACID BASE BALANCE; ACIDITY; ANION EXCHANGE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CELL PH; CLINICAL TRIAL (TOPIC); DIAGNOSTIC VALUE; DISEASE ACTIVITY; DRUG TARGETING; EXTRACELLULAR SPACE; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UPREGULATION; METABOLISM; NEOPLASM; PATHOLOGY; PH; PROGNOSIS;

ADENOSINE TRIPHOSPHATASES; CARBONIC ANHYDRASES; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; PROGNOSIS; SODIUM-HYDROGEN EXCHANGERS;

EID: 85009760475     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.12.003     Document Type: Review

References (260)

1. [1] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
2. [2] Gatenby, R.A., Gillies, R.J., Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4:11 (2004), 891–899.
3. [3] Warburg, O., On the origin of cancer cells. Science 123:3191 (1956), 309–314.
4. [4] Spugnini, E.P., Sonveaux, P., Stock, C., Perez-Sayans, M., De Milito, A., Avnet, S., Garcia, A.G., Harguindey, S., Fais, S., Proton channels and exchangers in cancer. Biochim. Biophys. Acta 1848:10 Pt B (2015), 2715–2726.
5. [5] Hernandez, A., Serrano-Bueno, G., Perez-Castineira, J.R., Serrano, A., Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer. Curr. Pharm. Des. 18:10 (2012), 1383–1394.
6. [6] Bublitz, M., Morth, J.P., Nissen, P., P-type ATPases at a glance. J. Cell Sci. 124:Pt 15 (2011), 2515–2519.
7. [7] Chi, S.L., Pizzo, S.V., Cell surface F1Fo ATP synthase: a new paradigm?. Ann. Med. 38:6 (2006), 429–438.
8. [8] Reshkin, S.J., Cardone, R.A., Harguindey, S., Na+-H+ exchanger, pH regulation and cancer. Recent Pat. Anticancer Drug Discov. 8:1 (2013), 85–99.
9. [9] Pinheiro, C., Longatto-Filho, A., Azevedo-Silva, J., Casal, M., Schmitt, F.C., Baltazar, F., Role of monocarboxylate transporters in human cancers: state of the art. J. Bioenerg. Biomembr. 44:1 (2012), 127–139.
10. [10] Pastorekova, S., Parkkila, S., Pastorek, J., Supuran, C.T., Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 19:3 (2004), 199–229.
11. [11] Morgan, P.E., Pastorekova, S., Stuart-Tilley, A.K., Alper, S.L., Casey, J.R., Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am. J. Physiol. Cell Physiol. 293:2 (2007), C738–748.
12. [12] Martinez-Outschoorn, U.E., Peiris-Pages, M., Pestell, R.G., Sotgia, F., Lisanti, M.P., Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol., 2016.
13. [13] Halestrap, A.P., The monocarboxylate transporter family–Structure and functional characterization. IUBMB Life 64:1 (2012), 1–9.
14. [14] Enerson, B.E., Drewes, L.R., Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci. 92:8 (2003), 1531–1544.
15. [15] Halestrap, A.P., The SLC16 gene family − structure, role and regulation in health and disease. Mol. Aspects Med. 34:2–3 (2013), 337–349.
16. [16] Céline Pinheiro FM-S, Sara Granja, Vera Miranda- Gonçalves, Julieta Afonso, Ricardo Amorim; Fátima Baltazar Targeting Metabolic Reprogramming as an Anti- Cancer Strategy: Aiming at Monocarboxylate Transporters In: Frontiers in Anti-Cancer Drug Discovery. Volume 6, edn. Edited by Atta-ur-Rahman F, M. Iqbal Choudhary: Bentham e books; 2016: 3–65.
17. [17] Granja, S., Marchiq, I., Le Floch, R., Moura, C.S., Baltazar, F., Pouyssegur, J., Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status. Oncotarget 6:9 (2015), 6708–6721.
18. [18] Pinheiro, C., Albergaria, A., Paredes, J., Sousa, B., Dufloth, R., Vieira, D., Schmitt, F., Baltazar, F., Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 56:7 (2010), 860–867.
19. [19] Simoes-Sousa, S., Granja, S., Pinheiro, C., Fernandes, D., Longatto-Filho, A., Laus, A.C., Alves, C.D., Suarez-Penaranda, J.M., Perez-Sayans, M., Lopes Carvalho, A., Prognostic significance of monocarboxylate transporter expression in oral cavity tumors. ABBV Cell Cycle 15:14 (2016), 1865–1873.
20. [20] Kim, Y., Choi, J.W., Lee, J.H., Kim, Y.S., Expression of lactate/H(+) symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. Hum. Pathol. 46:1 (2015), 104–112.
21. [21] Miranda-Goncalves, V., Honavar, M., Pinheiro, C., Martinho, O., Pires, M.M., Pinheiro, C., Cordeiro, M., Bebiano, G., Costa, P., Palmeirim, I., Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 15:2 (2013), 172–188.
22. [22] Pinheiro, C., Granja, S., Longatto-Filho, A., Faria, A.M., Fragoso, M.C., Lovisolo, S.M., Lerario, A.M., Almeida, M.Q., Baltazar, F., Zerbini, M.C., Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors. Oncotarget 6:42 (2015), 44403–44421.
23. [23] Ho, J., de Moura, M.B., Lin, Y., Vincent, G., Thorne, S., Duncan, L.M., Hui-Min, L., Kirkwood, J.M., Becker, D., Van Houten, B., Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol. Cancer, 11, 2012, 76.
24. [24] Schneiderhan, W., Scheler, M., Holzmann, K.H., Marx, M., Gschwend, J.E., Bucholz, M., Gress, T.M., Seufferlein, T., Adler, G., Oswald, F., CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in vivo and in vitro models. Gut 58:10 (2009), 1391–1398.
25. [25] Pinheiro, C., Longatto-Filho, A., Scapulatempo, C., Ferreira, L., Martins, S., Pellerin, L., Rodrigues, M., Alves, V.A., Schmitt, F., Baltazar, F., Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 452:2 (2008), 139–146.
26. [26] Chen, H., Wang, L., Beretov, J., Hao, J., Xiao, W., Li, Y., Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin. Exp. Metastasis 27:8 (2010), 557–569.
27. [27] Afonso, J., Longatto-Filho, A., Baltazar, F., Sousa, N., Costa, F.E., Morais, A., Amaro, T., Lopes, C., Santos, L.L., CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. Eur. J. Surg. Oncol. 37:9 (2011), 811–817.
28. [28] Pinheiro, C., Longatto-Filho, A., Ferreira, L., Pereira, S.M., Etlinger, D., Moreira, M.A., Jube, L.F., Queiroz, G.S., Schmitt, F., Baltazar, F., Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int. J. Gynecol. Pathol. 27:4 (2008), 568–574.
29. [29] Alves, V.A., Pinheiro, C., Morais-Santos, F., Felipe-Silva, A., Longatto-Filho, A., Baltazar, F., Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. World J. Gastroenterol. 20:33 (2014), 11780–11787.
30. [30] Pertega-Gomes, N., Vizcaino, J.R., Miranda-Goncalves, V., Pinheiro, C., Silva, J., Pereira, H., Monteiro, P., Henrique, R.M., Reis, R.M., Lopes, C., Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer, 11, 2011, 312.
31. [31] Koukourakis, M.I., Giatromanolaki, A., Bougioukas, G., Sivridis, E., Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol. Ther. 6:9 (2007), 1476–1479.
32. [32] Mathupala, S.P., Parajuli, P., Sloan, A.E., Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 55:6 (2004), 1410–1419.
33. [33] Koukourakis, M.I., Giatromanolaki, A., Harris, A.L., Sivridis, E., Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 66:2 (2006), 632–637.
34. [34] Pertega-Gomes, N., Vizcaino, J.R., Gouveia, C., Jeronimo, C., Henrique, R.M., Lopes, C., Baltazar, F., Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate 73:7 (2013), 763–769.
35. [35] Schell, J.C., Rutter, J., The long and winding road to the mitochondrial pyruvate carrier. Cancer Metab, 1(1), 2013, 6.
36. [36] Kumar, A., Kant, S., Singh, S.M., Targeting monocarboxylate transporter by alpha-cyano-4-hydroxycinnamate modulates apoptosis and cisplatin resistance of Colo205 cells: implication of altered cell survival regulation. Apoptosis 18:12 (2013), 1574–1585.
37. [37] Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M.C., Verrax, J., Rabbani, Z.N., De Saedeleer, C.J., Kennedy, K.M., Diepart, C., Jordan, B.F., Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118:12 (2008), 3930–3942.
38. [38] Morais-Santos, F., Miranda-Goncalves, V., Pinheiro, S., Vieira, A.F., Paredes, J., Schmitt, F.C., Baltazar, F., Pinheiro, C., Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. Endocr. Relat. Cancer 21:1 (2014), 27–38.
39. [39] Colen, C.B., Shen, Y., Ghoddoussi, F., Yu, P., Francis, T.B., Koch, B.J., Monterey, M.D., Galloway, M.P., Sloan, A.E., Mathupala, S.P., Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 13:7 (2011), 620–632.
40. [40] Ovens, M.J., Davies, A.J., Wilson, M.C., Murray, C.M., Halestrap, A.P., AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10. Biochem. J 425:3 (2010), 523–530.
41. [41] Le Floch, R., Chiche, J., Marchiq, I., Naiken, T., Ilc, K., Murray, C.M., Critchlow, S.E., Roux, D., Simon, M.P., Pouyssegur, J., CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. U. S. A. 108:40 (2011), 16663–16668.
42. [42] Polanski, R., Hodgkinson, C.L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P.W., White, A., Critchlow, S.E., Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin. Cancer Res. 20:4 (2014), 926–937.
43. [43] Afonso, J., Santos, L.L., Miranda-Goncalves, V., Morais, A., Amaro, T., Longatto-Filho, A., Baltazar, F., CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol. Carcinog. 54:11 (2015), 1451–1466.
44. [44] de Oliveira, A.T., Pinheiro, C., Longatto-Filho, A., Brito, M.J., Martinho, O., Matos, D., Carvalho, A.L., Vazquez, V.L., Silva, T.B., Scapulatempo, C., Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J. Bioenerg. Biomembr. 44:1 (2012), 171–178.
45. [45] Pinheiro, C., Longatto-Filho, A., Simoes, K., Jacob, C.E., Bresciani, C.J., Zilberstein, B., Cecconello, I., Alves, V.A., Schmitt, F., Baltazar, F., The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur. J. Cancer 45:13 (2009), 2418–2424.
46. [46] Pinheiro, C., Longatto-Filho, A., Pereira, S.M., Etlinger, D., Moreira, M.A., Jube, L.F., Queiroz, G.S., Schmitt, F., Baltazar, F., Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis. Markers 26:3 (2009), 97–103.
47. [47] Slomiany, M.G., Grass, G.D., Robertson, A.D., Yang, X.Y., Maria, B.L., Beeson, C., Toole, B.P., Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res. 69:4 (2009), 1293–1301.
48. [48] Baba, M., Inoue, M., Itoh, K., Nishizawa, Y., Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem. Biophys. Res. Commun. 374:1 (2008), 111–116.
49. [49] Xiong, L., Edwards, C.K. 3rd, Zhou, L., The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int. J. Mol. Sci. 15:10 (2014), 17411–17441.
50. [50] Kasinrerk, W., Tokrasinwit, N., Phunpae, P., CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway. Immunology 96:2 (1999), 184–192.
51. [51] A trial of AZD3965 for advanced cancer. 2016 http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-azd3965-for-advanced-cancer (Accessed 15 December 2016).
52. [52] Sakthivel, S., ATP-ase as a potential drug target for cancer, tumor growth and cellular functions. Int. J. Hum. Genet. 12:3 (2012), 151–156.
53. [53] Spugnini, E.P., Citro, G., Fais, S., Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J. Exp. Clin. Cancer Res., 29, 2010, 44.
54. [54] Hong, S., Pedersen, P.L., ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol. Mol. Biol. Rev. 72:4 (2008), 590–641.
55. [55] Mowery, Y.M., Pizzo, S.V., Targeting cell surface F1F0 ATP synthase in cancer therapy. Cancer Biol. Ther. 7:11 (2008), 1836–1838.
56. [56] Ma, Z., Cao, M., Liu, Y., He, Y., Wang, Y., Yang, C., Wang, W., Du, Y., Zhou, M., Gao, F., Mitochondrial F1Fo-ATP synthase translocates to cell surface in hepatocytes and has high activity in tumor-like acidic and hypoxic environment. Acta Biochim. Biophys. Sin. (Shanghai) 42:8 (2010), 530–537.
57. [57] E PPC: Ion motive ATPases. I. Ubiquity, properties, and significance to cell function. Trends Biochem. Sci.(12), 1987, 146–150.
58. [58] Thever, M.D., Saier, M.H. Jr., Bioinformatic characterization of p-type ATPases encoded within the fully sequenced genomes of 26 eukaryotes. J. Membr. Biol. 229:3 (2009), 115–130.
59. [59] Yatime, L., Buch-Pedersen, M.J., Musgaard, M., Morth, J.P., Lund Winther, A.M., Pedersen, B.P., Olesen, C., Andersen, J.P., Vilsen, B., Schiott, B., P-type ATPases as drug targets: tools for medicine and science. Biochim. Biophys. Acta 1787:4 (2009), 207–220.
60. [60] Lopez-Marques, R.L., Theorin, L., Palmgren, M.G., Pomorski, T.G., P4-ATPases: lipid flippases in cell membranes. Pflugers Arch. 466:7 (2014), 1227–1240.
61. [61] Shin, J.M., Munson, K., Vagin, O., Sachs, G., The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 457:3 (2009), 609–622.
62. [62] Shin, J.M., Kim, N., Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J. Neurogastroenterol. Motil. 19:1 (2013), 25–35.
63. [63] Pestov, N.B., Romanova, L.G., Korneenko, T.V., Egorov, M.V., Kostina, M.B., Sverdlov, V.E., Askari, A., Shakhparonov, M.I., Modyanov, N.N., Ouabain-sensitive H,K-ATPase: tissue-specific expression of the mammalian genes encoding the catalytic alpha subunit. FEBS Lett. 440:3 (1998), 320–324.
64. [64] Axelsen, K.B., Palmgren, M.G., Evolution of substrate specificities in the P-type ATPase superfamily. J. Mol. Evol. 46:1 (1998), 84–101.
65. [65] Streif, D., Iglseder, E., Hauser-Kronberger, C., Fink, K.G., Jakab, M., Ritter, M., Expression of the non-gastric H+/K+ ATPase ATP12A in normal and pathological human prostate tissue. Cell. Physiol. Biochem. 28:6 (2011), 1287–1294.
66. [66] Takahashi, Y., Sakai, H., Kuragari, M., Suzuki, T., Tauchi, K., Minamimura, T., Tsukada, K., Asano, S., Takeguchi, N., Expression of ATP1AL1, a non-gastric proton pump, in human colorectum. Jpn. J. Physiol. 52:3 (2002), 317–321.
67. [67] Toei, M., Saum, R., Forgac, M., Regulation and isoform function of the V-ATPases. Biochemistry 49:23 (2010), 4715–4723.
68. [68] Ma, Y., Yang, F., Wang, Y., Du, Z., Liu, D., Guo, H., Shen, J., Peng, H., CaMKKbeta is involved in AMP-activated protein kinase activation by baicalin in LKB1 deficient cell lines. PLoS One, 7(10), 2012, e47900.
69. [69] Ma, B., Xiang, Y., An, L., Structural bases of physiological functions and roles of the vacuolar H(+)-ATPase. Cell. Signal. 23:8 (2011), 1244–1256.
70. [70] Breton, S., Brown, D., New insights into the regulation of V-ATPase-dependent proton secretion. Am. J. Physiol. Renal Physiol. 292:1 (2007), F1–10.
71. [71] Sennoune, S.R., Luo, D., Martinez-Zaguilan, R., Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem. Biophys. 40:2 (2004), 185–206.
72. [72] Jefferies, K.C., Cipriano, D.J., Forgac, M., Function, structure and regulation of the vacuolar (H + )-ATPases. Arch. Biochem. Biophys. 476:1 (2008), 33–42.
73. [73] Nishisho, T., Hata, K., Nakanishi, M., Morita, Y., Sun-Wada, G.H., Wada, Y., Yasui, N., Yoneda, T., The a3 isoform vacuolar type H(+)-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol. Cancer Res. 9:7 (2011), 845–855.
74. [74] Lu, X., Chen, L., Chen, Y., Shao, Q., Qin, W., Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med 10:5 (2015), 1829–1834.
75. [75] Chung, C., Mader, C.C., Schmitz, J.C., Atladottir, J., Fitchev, P., Cornwell, M.L., Koleske, A.J., Crawford, S.E., Gorelick, F., The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab. Invest. 91:5 (2011), 732–743.
76. [76] Son, S.W., Kim, S.H., Moon, E.Y., Kim, D.H., Pyo, S., Um, S.H., Prognostic significance and function of the vacuolar H+-ATPase subunit V1E1 in esophageal squamous cell carcinoma. Oncotarget, 2016.
77. [77] Garcia-Garcia, A., Perez-Sayans Garcia, M., Rodriguez, M.J., Antunez-Lopez, J., Barros-Angueira, F., Somoza-Martin, M., Gandara-Rey, J.M., Aguirre-Urizar, J.M., Immunohistochemical localization of C1 subunit of V-ATPase (ATPase C1) in oral squamous cell cancer and normal oral mucosa. Biotech. Histochem. 87:2 (2012), 133–139.
78. [78] Xu, J., Xie, R., Liu, X., Wen, G., Jin, H., Yu, Z., Jiang, Y., Zhao, Z., Yang, Y., Ji, B., Expression and functional role of vacuolar H(+)-ATPase in human hepatocellular carcinoma. Carcinogenesis 33:12 (2012), 2432–2440.
79. [79] Lu, Q., Lu, S., Huang, L., Wang, T., Wan, Y., Zhou, C.X., Zhang, C., Zhang, Z., Li, X., The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn. Pathol., 8, 2013, 145.
80. [80] Di Cristofori, A., Ferrero, S., Bertolini, I., Gaudioso, G., Russo, M.V., Berno, V., Vanini, M., Locatelli, M., Zavanone, M., Rampini, P., The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma. Oncotarget 6:19 (2015), 17514–17531.
81. [81] Kulshrestha, A., Katara, G.K., Ibrahim, S., Pamarthy, S., Jaiswal, M.K., Gilman Sachs, A., Beaman, K.D., Vacuolar ATPase ‘a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer. Oncotarget 6:6 (2015), 3797–3810.
82. [82] Liu, P., Chen, H., Han, L., Zou, X., Shen, W., Expression and role of V1A subunit of V-ATPases in gastric cancer cells. Int. J. Clin. Oncol. 20:4 (2015), 725–735.
83. [83] Song, T., Jeon, H.K., Hong, J.E., Choi, J.J., Kim, T.J., Choi, C.H., Bae, D.S., Kim, B.G., Lee, J.W., Proton pump inhibition enhances the cytotoxicity of paclitaxel in cervical cancer. Cancer Res. Treat., 2016.
84. [84] Cotter, K., Liberman, R., Sun-Wada, G., Wada, Y., Sgroi, D., Naber, S., Brown, D., Breton, S., Forgac, M., The a3 isoform of subunit a of the vacuolar ATPase localizes to the plasma membrane of invasive breast tumor cells and is overexpressed in human breast cancer. Oncotarget, 2016.
85. [85] Perez-Sayans, M., Somoza-Martin, J.M., Barros-Angueira, F., Rey, J.M., Garcia-Garcia, A., V-ATPase inhibitors and implication in cancer treatment. Cancer Treat. Rev. 35:8 (2009), 707–713.
86. [86] Hinton, A., Sennoune, S.R., Bond, S., Fang, M., Reuveni, M., Sahagian, G.G., Jay, D., Martinez-Zaguilan, R., Forgac, M., Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J. Biol. Chem. 284:24 (2009), 16400–16408.
87. [87] Otero-Rey, E.M., Somoza-Martin, M., Barros-Angueira, F., Garcia-Garcia, A., Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene. Oral Oncol. 44:2 (2008), 193–199.
88. [88] Lu, X., Qin, W., Li, J., Tan, N., Pan, D., Zhang, H., Xie, L., Yao, G., Shu, H., Yao, M., The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 65:15 (2005), 6843–6849.
89. [89] Xu, X., You, J., Pei, F., Silencing of a novel tumor metastasis suppressor gene LASS2/TMSG1 promotes invasion of prostate cancer cell in vitro through increase of vacuolar ATPase activity. J. Cell. Biochem. 113:7 (2012), 2356–2363.
90. [90] Daniel, C., Bell, C., Burton, C., Harguindey, S., Reshkin, S.J., Rauch, C., The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochim. Biophys. Acta 1832:5 (2013), 606–617.
91. [91] Larsen, A.K., Escargueil, A.E., Skladanowski, A., Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 85:3 (2000), 217–229.
92. [92] You, H., Jin, J., Shu, H., Yu, B., De Milito, A., Lozupone, F., Deng, Y., Tang, N., Yao, G., Fais, S., Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells. Cancer Lett. 280:1 (2009), 110–119.
93. [93] Harguindey, S., Orive, G., Luis Pedraz, J., Paradiso, A., Reshkin, S.J., The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin–one single nature. Biochim. Biophys. Acta 1 (1756), 1–24.
94. [94] Thews, O., Gassner, B., Kelleher, D.K., Schwerdt, G., Gekle, M., Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 8:2 (2006), 143–152.
95. [95] Drose, S., Altendorf, K., Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J. Exp. Biol. 200:Pt 1 (1997), 1–8.
96. [96] Walsh, M., Fais, S., Spugnini, E.P., Harguindey, S., Abu Izneid, T., Scacco, L., Williams, P., Allegrucci, C., Rauch, C., Omran, Z., Proton pump inhibitors for the treatment of cancer in companion animals. J. Exp. Clin. Cancer Res., 34, 2015, 93.
97. [97] Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst. 96:22 (2004), 1702–1713.
98. [98] De Milito, A., Fais, S., Proton pump inhibitors may reduce tumour resistance. Expert Opin. Pharmacother. 6:7 (2005), 1049–1054.
99. [99] Ward, R.M., Kearns, G.L., Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr. Drugs 15:2 (2013), 119–131.
100. [100] Schwartz, M.D., Dyspepsia, peptic ulcer disease, and esophageal reflux disease. West. J. Med. 176:2 (2002), 98–103.
101. [101] Kendall, M.J., Review article: esomeprazole–the first proton pump inhibitor to be developed as an isomer. Aliment. Pharmacol. Ther. 17:Suppl. 1 (2003), 1–4.
102. [102] Parks, S.K., Chiche, J., Pouyssegur, J., Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 13:9 (2013), 611–623.
103. [103] Fais, S., Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J. Intern. Med. 267:5 (2010), 515–525.
104. [104] Yeo, M., Kim, D.K., Kim, Y.B., Oh, T.Y., Lee, J.E., Cho, S.W., Kim, H.C., Hahm, K.B., Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin. Cancer Res. 10:24 (2004), 8687–8696.
105. [105] De Milito, A., Canese, R., Marino, M.L., Borghi, M., Iero, M., Villa, A., Venturi, G., Lozupone, F., Iessi, E., Logozzi, M., pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int. J. Cancer 127:1 (2010), 207–219.
106. [106] Goh, W., Sleptsova-Freidrich, I., Petrovic, N., Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J. Pharm. Pharm. Sci. 17:3 (2014), 439–446.
107. [107] Perez-Sayans, M., Somoza-Martin, J.M., Barros-Angueira, F., Diz, P.G., Rey, J.M., Garcia-Garcia, A., Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett. 295:2 (2010), 135–143.
108. [108] De Milito, A., Iessi, E., Logozzi, M., Lozupone, F., Spada, M., Marino, M.L., Federici, C., Perdicchio, M., Matarrese, P., Lugini, L., Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 67:11 (2007), 5408–5417.
109. [109] Ferrari, S., Perut, F., Fagioli, F., Brach Del Prever, A., Meazza, C., Parafioriti, A., Picci, P., Gambarotti, M., Avnet, S., Baldini, N., Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J. Transl. Med., 11, 2013, 268.
110. [110] Lindner, K., Borchardt, C., Schopp, M., Burgers, A., Stock, C., Hussey, D.J., Haier, J., Hummel, R., Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J. Exp. Clin. Cancer Res., 33, 2014, 73.
111. [111] Lee, Y.Y., Jeon, H.K., Hong, J.E., Cho, Y.J., Ryu, J.Y., Choi, J.J., Lee, S.H., Yoon, G., Kim, W.Y., Do, I.G., Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget 6:33 (2015), 35040–35050.
112. [112] Perona, R., Portillo, F., Giraldez, F., Serrano, R., Transformation and pH homeostasis of fibroblasts expressing yeast H(+)-ATPase containing site-directed mutations. Mol. Cell. Biol. 10:8 (1990), 4110–4115.
113. [113] Huang, T.C., Chang, H.Y., Hsu, C.H., Kuo, W.H., Chang, K.J., Juan, H.F., Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J. Proteome Res. 7:4 (2008), 1433–1444.
114. [114] Mgbonyebi, O.P., Russo, J., Russo, I.H., Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12:4 (1998), 865–869.
115. [115] Mahyar-Roemer, M., Katsen, A., Mestres, P., Roemer, K., Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int. J. Cancer 94:5 (2001), 615–622.
116. [116] Ding, X.Z., Adrian, T.E., Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25:4 (2002), e71–76.
117. [117] Atten, M.J., Attar, B.M., Milson, T., Holian, O., Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem. Pharmacol. 62:10 (2001), 1423–1432.
118. [118] Hsieh, T.C., Wu, J.M., Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res. 20:1a (2000), 225–228.
119. [119] Billard, C., Izard, J.C., Roman, V., Kern, C., Mathiot, C., Mentz, F., Kolb, J.P., Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk. Lymphoma 43:10 (2002), 1991–2002.
120. [120] Chi, S.L., Pizzo, S.V., Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res. 66:2 (2006), 875–882.
121. [121] Wang, B.Y., Zhang, J., Wang, J.L., Sun, S., Wang, Z.H., Wang, L.P., Zhang, Q.L., Lv, F.F., Cao, E.Y., Shao, Z.M., Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J. Exp. Clin. Cancer Res., 34, 2015, 85.
122. [122] Fais, S., Evidence-based support for the use of proton pump inhibitors in cancer therapy. J. Transl. Med., 13, 2015, 368.
123. [123] Chu, M.P., Hecht, J.R., Slamon, D., Wainberg, Z.A., Bang, Y.J., Hoff, P.M., Sobrero, A., Qin, S., Afenjar, K., Houe, V., Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol., 2016.
124. [124] Donowitz, M., Ming Tse, C., Fuster, D., SLC9/NHE gene family, a plasma membrane and organellar family of Na(+)/H(+) exchangers. Mol. Aspects Med. 34:2–3 (2013), 236–251.
125. [125] Fuster, D.G., Alexander, R.T., Traditional and emerging roles for the SLC9 Na+/H+ exchangers. Pflugers Arch. 466:1 (2014), 61–76.
126. [126] Amith, S.R., Fong, S., Baksh, S., Fliegel, L., Na (+)/H (+)exchange in the tumour microenvironment: does NHE1 drive breast cancer carcinogenesis?. Int. J. Dev. Biol. 59:7–9 (2015), 367–377.
127. [127] Amith, S.R., Fliegel, L., Regulation of the Na+/H+ exchanger (NHE1) in Breast cancer metastasis. Cancer Res. 73:4 (2013), 1259–1264.
128. [128] Cardone, R.A., Casavola, V., Reshkin, S.J., The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat. Rev. Cancer 5:10 (2005), 786–795.
129. [129] Rauch, C., On the relationship between drug's size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data. Eur. Biophys. J. 38:4 (2009), 537–546.
130. [130] Harguindey, S., Cragoe, E.J. Jr., The Na+/H+ antiporter in oncology in the light of the spontaneous regression of cancer and cell metabolism. Med. Hypotheses 39:3 (1992), 229–237.
131. [131] Chiang, Y., Chou, C.Y., Hsu, K.F., Huang, Y.F., Shen, M.R., EGF upregulates Na+/H+ exchanger NHE1 by post-translational regulation that is important for cervical cancer cell invasiveness. J. Cell. Physiol. 214:3 (2008), 810–819.
132. [132] Yang, X., Wang, D., Dong, W., Song, Z., Dou, K., Expression and modulation of Na(+)/H(+) exchanger 1 gene in hepatocellular carcinoma: a potential therapeutic target. J. Gastroenterol. Hepatol. 26:2 (2011), 364–370.
133. [133] Guan, B., Hoque, A., Xu, X., Amiloride and guggulsterone suppression of esophageal cancer cell growth in vitro and in nude mouse xenografts. Front. Biol. (Beijing) 9:1 (2014), 75–81.
134. [134] Boedtkjer, E., Moreira, J.M., Mele, M., Vahl, P., Wielenga, V.T., Christiansen, P.M., Jensen, V.E., Pedersen, S.F., Aalkjaer, C., Contribution of Na+,HCO3(−)-cotransport to cellular pH control in human breast cancer: a role for the breast cancer susceptibility locus NBCn1 (SLC4A7). Int. J. Cancer 132:6 (2013), 1288–1299.
135. [135] Cong, D., Zhu, W., Shi, Y., Pointer, K.B., Clark, P.A., Shen, H., Kuo, J.S., Hu, S., Sun, D., Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H(+) extrusion, cell migration and survival. Carcinogenesis 35:9 (2014), 2014–2024.
136. [136] Yang, X., Wang, D., Dong, W., Song, Z., Dou, K., Over-expression of Na+/H+ exchanger 1 and its clinicopathologic significance in hepatocellular carcinoma. Med. Oncol. 27:4 (2010), 1109–1113.
137. [137] Wakabayashi, S., Shigekawa, M., Pouyssegur, J., Molecular physiology of vertebrate Na+/H+ exchangers. Physiol. Rev. 77:1 (1997), 51–74.
138. [138] Reshkin, S.J., Bellizzi, A., Albarani, V., Guerra, L., Tommasino, M., Paradiso, A., Casavola, V., Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J. Biol. Chem. 275:8 (2000), 5361–5369.
139. [139] Vahle, A.K., Domikowsky, B., Schwoppe, C., Krahling, H., Mally, S., Schafers, M., Hermann, S., Shahin, V., Haier, J., Schwab, A., Extracellular matrix composition and interstitial pH modulate NHE1-mediated melanoma cell motility. Int. J. Oncol. 44:1 (2014), 78–90.
140. [140] Cardone, R.A., Greco, M.R., Zeeberg, K., Zaccagnino, A., Saccomano, M., Bellizzi, A., Bruns, P., Menga, M., Pilarsky, C., Schwab, A., A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. Neoplasia 17:2 (2015), 155–166.
141. [141] Harguindey, S., Arranz, J.L., Polo Orozco, J.D., Rauch, C., Fais, S., Cardone, R.A., Reshkin, S.J., Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs–an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. J. Transl. Med., 11, 2013, 282.
142. [142] Harguindey, S., Use of Na+/H+ antiporter inhibitors as a novel approach to cancer treatment. Cragoe, E.J., (eds.) Amiloride and Its Analogs: Unique Cation Transport Inhibitors, 1992, Weinheim and Cambridge: VCH Publishers Inc, New York, 317–334.
143. [143] Sparks, R.L., Pool, T.B., Smith, N.K., Cameron, I.L., Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo. Cancer Res. 43:1 (1983), 73–77.
144. [144] Giusti, I., D'Ascenzo, S., Millimaggi, D., Taraboletti, G., Carta, G., Franceschini, N., Pavan, A., Dolo, V., Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 10:5 (2008), 481–488.
145. [145] Matthews, H., Ranson, M., Kelso, M.J., Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?. Int. J. Cancer 129:9 (2011), 2051–2061.
146. [146] Harley, W., Floyd, C., Dunn, T., Zhang, X.D., Chen, T.Y., Hegde, M., Palandoken, H., Nantz, M.H., Leon, L., Carraway, K.L. 3rd, Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas. Brain Res. 1363 (2010), 159–169.
147. [147] Yang, X., Wang, D., Dong, W., Song, Z., Dou, K., Inhibition of Na(+)/H(+) exchanger 1 by 5-(N-ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and motility. Cancer Lett. 295:2 (2010), 198–204.
148. [148] Wong, P., Kleemann, H.W., Tannock, I.F., Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br. J. Cancer 87:2 (2002), 238–245.
149. [149] Rich, I.N., Worthington-White, D., Garden, O.A., Musk, P., Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood 95:4 (2000), 1427–1434.
150. [150] Garcı́a-Cañero, R., Trilla, C., Pérez de Diego, J., Dı́az-Gil, J.J., Cobo, J.M., Na+:H+ exchange inhibition induces intracellular acidosis and differentially impairs cell growth and viability of human and rat hepatocarcinoma cells. Toxicol. Lett. 106:2–3 (1999), 215–228.
151. [151] Reshkin, S.J., Bellizzi, A., Cardone, R.A., Tommasino, M., Casavola, V., Paradiso, A., Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin. Cancer Res. 9:6 (2003), 2366–2373.
152. [152] Jin, W., Li, Q., Wang, J., Chang, G., Lin, Y., Li, H., Wang, L., Gao, W., Pang, T., Na+/H+ exchanger 1 inhibition contributes to K562 leukaemic cell differentiation. Cell Biol. Int. 36:8 (2012), 739–745.
153. [153] Di Sario, A., Bendia, E., Omenetti, A., De Minicis, S., Marzioni, M., Kleemann, H.W., Candelaresi, C., Saccomanno, S., Alpini, G., Benedetti, A., Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells. Dig. Liver Dis. 39:1 (2007), 60–69.
154. [154] Lv, C., Yang, X., Yu, B., Ma, Q., Liu, B., Liu, Y., Blocking the Na+/H+ exchanger 1 with cariporide (HOE642) reduces the hypoxia-induced invasion of human tongue squamous cell carcinoma. Int. J. Oral Maxillofac. Surg. 41:10 (2012), 1206–1210.
155. [155] Nagata, H., Che, X.F., Miyazawa, K., Tomoda, A., Konishi, M., Ubukata, H., Tabuchi, T., Rapid decrease of intracellular pH associated with inhibition of Na+/H+ exchanger precedes apoptotic events in the MNK45 and MNK74 gastric cancer cell lines treated with 2-aminophenoxazine-3-one. Oncol. Rep. 25:2 (2011), 341–346.
156. [156] Che, X.F., Zheng, C.L., Akiyama, S., Tomoda, A., 2-Aminophenoxazine-3-one and 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher intracellular pH in cancer cells. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 87:4 (2011), 199–213.
157. [157] Atwal, K.S., O'Neil, S.V., Ahmad, S., Doweyko, L., Kirby, M., Dorso, C.R., Chandrasena, G., Chen, B.C., Zhao, R., Zahler, R., Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors. Bioorg. Med. Chem. Lett. 16:18 (2006), 4796–4799.
158. [158] Aihara, K., Hisa, H., Sato, T., Yoneyama, F., Sasamori, J., Yamaguchi, F., Yoneyama, S., Mizuno, Y., Takahashi, A., Nagai, A., et al. Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury. Eur. J. Pharmacol. 404:1–2 (2000), 221–229.
159. [159] Fukumoto, S., Imamiya, E., Kusumoto, K., Fujiwara, S., Watanabe, T., Shiraishi, M., Novel, non-acylguanidine-type Na(+)/H(+) exchanger inhibitors: synthesis and pharmacology of 5-tetrahydroquinolinylidene aminoguanidine derivatives. J. Med. Chem. 45:14 (2002), 3009–3021.
160. [160] Rupprecht, H.J., vom Dahl, J., Terres, W., Seyfarth, K.M., Richardt, G., Schultheibeta, H.P., Buerke, M., Sheehan, F.H., Drexler, H., Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 101:25 (2000), 2902–2908.
161. [161] Mentzer, R.M. Jr., Bartels, C., Bolli, R., Boyce, S., Buckberg, G.D., Chaitman, B., Haverich, A., Knight, J., Menasche, P., Myers, M.L., Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann. Thorac. Surg. 85:4 (2008), 1261–1270.
162. [162] Zeymer, U., Suryapranata, H., Monassier, J.P., Opolski, G., Davies, J., Rasmanis, G., Linssen, G., Tebbe, U., Schroder, R., Tiemann, R., The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J. Am. Coll. Cardiol. 38:6 (2001), 1644–1650.
163. [163] Avkiran, M., Cook, A.R., Cuello, F., Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach?. Curr. Opin. Pharmacol. 8:2 (2008), 133–140.
164. [164] Chiche, J., Ilc, K., Brahimi-Horn, M.C., Pouyssegur, J., Membrane-bound carbonic anhydrases are key pH regulators controlling tumor growth and cell migration. Adv. Enzyme Regul. 50:1 (2010), 20–33.
165. [165] Imtaiyaz Hassan, M., Shajee, B., Waheed, A., Ahmad, F., Sly, W.S., Structure, function and applications of carbonic anhydrase isozymes. Bioorg. Med. Chem. 21:6 (2013), 1570–1582.
166. [166] Wykoff, C.C., Beasley, N.J., Watson, P.H., Turner, K.J., Pastorek, J., Sibtain, A., Wilson, G.D., Turley, H., Talks, K.L., Maxwell, P.H., Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60:24 (2000), 7075–7083.
167. [167] Wykoff, C.C., Beasley, N., Watson, P.H., Campo, L., Chia, S.K., English, R., Pastorek, J., Sly, W.S., Ratcliffe, P., Harris, A.L., Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 158:3 (2001), 1011–1019.
168. [168] Pinheiro, C., Sousa, B., Albergaria, A., Paredes, J., Dufloth, R., Vieira, D., Schmitt, F., Baltazar, F., GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol. Histopathol. 26:10 (2011), 1279–1286.
169. [169] Yang, J.S., Chen, M.K., Yang, S.F., Chang, Y.C., Su, S.C., Chiou, H.L., Chien, M.H., Lin, C.W., Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma. Clin. Chem. Lab. Med. 52:9 (2014), 1367–1377.
170. [170] Ilie, M., Mazure, N.M., Hofman, V., Ammadi, R.E., Ortholan, C., Bonnetaud, C., Havet, K., Venissac, N., Mograbi, B., Mouroux, J., High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br. J. Cancer 102:11 (2010), 1627–1635.
171. [171] Miranda-Goncalves, V., Reis, R.M., Baltazar, F., Lactate transporters and pH regulation: potential therapeutic targets in glioblastomas. Curr. Cancer Drug Targets 16:5 (2016), 388–399.
172. [172] de Martino, M., Lucca, I., Mbeutcha, A., Wiener, H.G., Haitel, A., Susani, M., Shariat, S.F., Klatte, T., Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. Eur. Urol. 68:4 (2015), 552–554.
173. [173] Hynninen, P., Vaskivuo, L., Saarnio, J., Haapasalo, H., Kivela, J., Pastorekova, S., Pastorek, J., Waheed, A., Sly, W.S., Puistola, U., Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49:6 (2006), 594–602.
174. [174] Tafreshi, N.K., Lloyd, M.C., Bui, M.M., Gillies, R.J., Morse, D.L., Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell. Biochem. 75 (2014), 221–254.
175. [175] Li, J., Zhang, G., Wang, X., Li, X.F., Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?. Future Oncol. 11:10 (2015), 1531–1541.
176. [176] Choueiri, T.K., Regan, M.M., Rosenberg, J.E., Oh, W.K., Clement, J., Amato, A.M., McDermott, D., Cho, D.C., Atkins, M.B., Signoretti, S., Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 106:6 (2010), 772–778.
177. [177] Maroto, P., Rini, B., Molecular biomarkers in advanced renal cell carcinoma. Clin. Cancer Res. 20:8 (2014), 2060–2071.
178. [178] Hong, Y.S., Cho, H.J., Kim, S.Y., Jung, K.H., Park, J.W., Choi, H.S., Oh, J.H., Kim, B.C., Sohn, D.K., Kim, D.Y., Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer, 9, 2009, 246.
179. [179] Betof, A.S., Rabbani, Z.N., Hardee, M.E., Kim, S.J., Broadwater, G., Bentley, R.C., Snyder, S.A., Vujaskovic, Z., Oosterwijk, E., Harris, L.N., Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br. J. Cancer 106:5 (2012), 916–922.
180. [180] Aomatsu, N., Yashiro, M., Kashiwagi, S., Kawajiri, H., Takashima, T., Ohsawa, M., Wakasa, K., Hirakawa, K., Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline. BMC Cancer, 14, 2014, 400.
181. [181] Pastorek, J., Pastorekova, S., Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin. Cancer Biol. 31 (2015), 52–64.
182. [182] Kivela, A., Parkkila, S., Saarnio, J., Karttunen, T.J., Kivela, J., Parkkila, A.K., Waheed, A., Sly, W.S., Grubb, J.H., Shah, G., Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am. J. Pathol. 156:2 (2000), 577–584.
183. [183] Yoo, C.W., Nam, B.H., Kim, J.Y., Shin, H.J., Lim, H., Lee, S., Lee, S.K., Lim, M.C., Song, Y.J., Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. Radiat. Oncol., 5, 2010, 101.
184. [184] Parkkila, S., Parkkila, A.K., Saarnio, J., Kivela, J., Karttunen, T.J., Kaunisto, K., Waheed, A., Sly, W.S., Tureci, O., Virtanen, I., Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J. Histochem. Cytochem. 48:12 (2000), 1601–1608.
185. [185] Ilie, M.I., Hofman, V., Ortholan, C., Ammadi, R.E., Bonnetaud, C., Havet, K., Venissac, N., Mouroux, J., Mazure, N.M., Pouyssegur, J., Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int. J. Cancer 128:7 (2011), 1614–1623.
186. [186] Kivela, A.J., Parkkila, S., Saarnio, J., Karttunen, T.J., Kivela, J., Parkkila, A.K., Pastorekova, S., Pastorek, J., Waheed, A., Sly, W.S., Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem. Cell Biol. 114:3 (2000), 197–204.
187. [187] Watson, P.H., Chia, S.K., Wykoff, C.C., Han, C., Leek, R.D., Sly, W.S., Gatter, K.C., Ratcliffe, P., Harris, A.L., Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br. J. Cancer 88:7 (2003), 1065–1070.
188. [188] Chien, M.H., Ying, T.H., Hsieh, Y.H., Lin, C.H., Shih, C.H., Wei, L.H., Yang, S.F., Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol. 48:5 (2012), 417–423.
189. [189] Haapasalo, J., Hilvo, M., Nordfors, K., Haapasalo, H., Parkkila, S., Hyrskyluoto, A., Rantala, I., Waheed, A., Sly, W.S., Pastorekova, S., Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol. 10:2 (2008), 131–138.
190. [190] Kobayashi, M., Matsumoto, T., Ryuge, S., Yanagita, K., Nagashio, R., Kawakami, Y., Goshima, N., Jiang, S.X., Saegusa, M., Iyoda, A., et al. CAXII Is a sero-diagnostic marker for lung cancer. PLoS One, 7(3), 2012, e33952.
191. [191] Tafreshi, N.K., Bui, M.M., Bishop, K., Lloyd, M.C., Enkemann, S.A., Lopez, A.S., Abrahams, D., Carter, B.W., Vagner, J., Grobmyer, S.R., Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin. Cancer Res. 18:1 (2012), 207–219.
192. [192] Supuran, C.T., Winum, J.Y., Carbonic anhydrase IX inhibitors in cancer therapy: an update. Future Med. Chem. 7:11 (2015), 1407–1414.
193. [193] Zatovicova, M., Jelenska, L., Hulikova, A., Csaderova, L., Ditte, Z., Ditte, P., Goliasova, T., Pastorek, J., Pastorekova, S., Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Des. 16:29 (2010), 3255–3263.
194. [194] Dubois, L., Lieuwes, N.G., Maresca, A., Thiry, A., Supuran, C.T., Scozzafava, A., Wouters, B.G., Lambin, P., Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother. Oncol. 92:3 (2009), 423–428.
195. [195] Chiche, J., Ilc, K., Laferriere, J., Trottier, E., Dayan, F., Mazure, N.M., Brahimi-Horn, M.C., Pouyssegur, J., Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 69:1 (2009), 358–368.
196. [196] Gondi, G., Mysliwietz, J., Hulikova, A., Jen, J.P., Swietach, P., Kremmer, E., Zeidler, R., Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res. 73:21 (2013), 6494–6503.
197. [197] Chiche, J., Brahimi-Horn, M.C., Pouyssegur, J., Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med. 14:4 (2010), 771–794.
198. [198] Svastova, E., Witarski, W., Csaderova, L., Kosik, I., Skvarkova, L., Hulikova, A., Zatovicova, M., Barathova, M., Kopacek, J., Pastorek, J., Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J. Biol. Chem. 287:5 (2012), 3392–3402.
199. [199] Parks, S.K., Cormerais, Y., Marchiq, I., Pouyssegur, J., Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export. Mol. Aspects Med. 47:48 (2016), 3–14.
200. [200] Doyen, J., Parks, S.K., Marcie, S., Pouyssegur, J., Chiche, J., Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. Front. Oncol., 2, 2012, 199.
201. [201] Dubois, L., Peeters, S., Lieuwes, N.G., Geusens, N., Thiry, A., Wigfield, S., Carta, F., McIntyre, A., Scozzafava, A., Dogne, J.M., Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother. Oncol. 99:3 (2011), 424–431.
202. [202] Aggarwal, M., McKenna, R., Update on carbonic anhydrase inhibitors: a patent review (2008 − 2011). Expert Opin. Ther. Pat. 22:8 (2012), 903–915.
203. [203] Supuran, C.T., Briganti, F., Tilli, S., Chegwidden, W.R., Scozzafava, A., Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?. Bioorg. Med. Chem. 9:3 (2001), 703–714.
204. [204] Lock, F.E., McDonald, P.C., Lou, Y., Serrano, I., Chafe, S.C., Ostlund, C., Aparicio, S., Winum, J.Y., Supuran, C.T., Dedhar, S., Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 32:44 (2013), 5210–5219.
205. [205] Touisni, N., Maresca, A., McDonald, P.C., Lou, Y., Scozzafava, A., Dedhar, S., Winum, J.Y., Supuran, C.T., Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J. Med. Chem. 54:24 (2011), 8271–8277.
206. [206] Gieling, R.G., Babur, M., Mamnani, L., Burrows, N., Telfer, B.A., Carta, F., Winum, J.Y., Scozzafava, A., Supuran, C.T., Williams, K.J., Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J. Med. Chem. 55:11 (2012), 5591–5600.
207. [207] Kopecka, J., Campia, I., Jacobs, A., Frei, A.P., Ghigo, D., Wollscheid, B., Riganti, C., Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget 6:9 (2015), 6776–6793.
208. [208] Hsieh, M.J., Chen, K.S., Chiou, H.L., Hsieh, Y.S., Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. Eur. J. Cell Biol. 89:8 (2010), 598–606.
209. [209] Battke, C., Kremmer, E., Mysliwietz, J., Gondi, G., Dumitru, C., Brandau, S., Lang, S., Vullo, D., Supuran, C., Zeidler, R., Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol. Immunother. 60:5 (2011), 649–658.
210. [210] Parkkila, S., Innocenti, A., Kallio, H., Hilvo, M., Scozzafava, A., Supuran, C.T., The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg. Med. Chem. Lett. 19:15 (2009), 4102–4106.
211. [211] Li, G., Feng, G., Gentil-Perret, A., Genin, C., Tostain, J., Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol. 180:2 (2008), 510–514.
212. [212] Siebels, M., Rohrmann, K., Oberneder, R., Stahler, M., Haseke, N., Beck, J., Hofmann, R., Kindler, M., Kloepfer, P., Stief, C., A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J. Urol. 29:1 (2011), 121–126.
213. [213] Belldegrun, A.S.C.K., Kloepfer, P., Fall, B., Bevan, P., Störkel, S., ARISER:a randomized double blind phase III study to evaluate adjuvant cG250treatment versus placebo in patients with high-risk ccRCC −results andimplications for adjuvant clinical trials. J. Clin. Oncol., 31(Suppl), 2013 (Abstr 4507).
214. [214] Thornell, I.M., Bevensee, M.O., Regulators of Slc4 bicarbonate transporter activity. Front. Physiol., 6, 2015, 166.
215. [215] Liu, Y., Yang, J., Chen, L.M., Structure and function of SLC4 family HCO3- transporters. Front. Physiol., 6, 2015.
216. [216] Romero, M.F., The SLC4 family of bicarbonate (HCO3-). Transporters 34:2–3 (2013), 159–182.
217. [217] Fu, G.H., Wang, Y., Xi, Y.H., Shen, W.W., Pan, X.Y., Shen, W.Z., Jiang, X.S., Chen, G.Q., Direct interaction and cooperative role of tumor suppressor p16 with band 3 (AE1). FEBS Lett. 579:10 (2005), 2105–2110.
218. [218] Sterling, D., Alvarez, B.V., Casey, J.R., The extracellular component of a transport metabolon. Extracellular loop 4 of the human AE1 Cl-/HCO3- exchanger binds carbonic anhydrase IV. J. Biol. Chem. 277:28 (2002), 25239–25246.
219. [219] Alrefai, W.A., Tyagi, S., Nazir, T.M., Barakat, J., Anwar, S.S., Hadjiagapiou, C., Bavishi, D., Sahi, J., Malik, P., Goldstein, J., Human intestinal anion exchanger isoforms: expression, distribution, and membrane localization. Biochim. Biophys. Acta 1511:1 (2001), 17–27.
220. [220] Shen, W.W., Wu, J., Cai, L., Liu, B.Y., Gao, Y., Chen, G.Q., Fu, G.H., Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma. Neoplasia 9:10 (2007), 812–819.
221. [221] Xu, W.Q., Song, L.J., Liu, Q., Zhao, L., Zheng, L., Yan, Z.W., Fu, G.H., Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer. J. Cancer Res. Clin. Oncol. 135:10 (2009), 1323–1330.
222. [222] Kay, M.M., Vollard, C.H., Human erythroid band 3 anion exchanger 1 is expressed in transformed lymphocytes. Cell. Mol. Biol. (Noisy-le-grand) 42:7 (1996), 945–952.
223. [223] Nehls, V., Zeitler-Zapf, P., Drenckhahn, D., Different sequences of expression of band 3, spectrin, and ankyrin during normal erythropoiesis and erythroleukemia. Am. J. Pathol. 142:5 (1993), 1565–1573.
224. [224] Song, L.J., Liu, R.J., Zeng, Z., Alper, S.L., Cui, H.J., Lu, Y., Zheng, L., Yan, Z.W., Fu, G.H., Gastrin inhibits a novel, pathological colon cancer signaling pathway involving EGR1, AE2, and P-ERK. J. Mol. Med. (Berl) 90:6 (2012), 707–718.
225. [225] Wu, T.T., Hsieh, Y.H., Wu, C.C., Tsai, J.H., Hsieh, Y.S., Huang, C.Y., Liu, J.Y., Overexpression of anion exchanger 2 in human hepatocellular carcinoma. Chin. J. Physiol. 49:4 (2006), 192–198.
226. [226] Yang, Y., Wu, P.P., Wu, J., Shen, W.W., Wu, Y.L., Fu, A.F., Zheng, L., Jin, X.L., Fu, G.H., Expression of anion exchanger 2 in human gastric cancer. Exp. Oncol. 30:1 (2008), 81–87.
227. [227] Wang, T., Fei, H.J., Yang, Y., Jiang, X.S., Yan, M., Zeng, Z., Wu, J., Song, L.J., Tian, H., Fu, G.H., Expression of AE1/p16 promoted degradation of AE2 in gastric cancer cells. BMC Cancer, 16, 2016, 716.
228. [228] Tang, X.B., Casey, J.R., Trapping of inhibitor-induced conformational changes in the erythrocyte membrane anion exchanger AE1. Biochemistry 38:44 (1999), 14565–14572.
229. [229] Halestrap, A.P., Meredith, D., The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 447:5 (2004), 619–628.
230. [230] Halestrap, A.P., Price, N.T., The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J 343:Pt 2 (1999), 281–299.
231. [231] Morgan, P.E., Supuran, C.T., Casey, J.R., Carbonic anhydrase inhibitors that directly inhibit anion transport by the human Cl-/HCO3- exchanger, AE1. Mol. Membr. Biol. 21:6 (2004), 423–433.
232. [232] Alper, S.L., Chernova, M.N., Williams, J., Zasloff, M., Law, F.Y., Knauf, P.A., Differential inhibition of AE1 and AE2 anion exchangers by oxonol dyes and by novel polyaminosterol analogs of the shark antibiotic squalamine. Biochem. Cell Biol. 76:5 (1998), 799–806.
233. [233] Suo, W.H., Zhang, N., Wu, P.P., Zhao, L., Song, L.J., Shen, W.W., Zheng, L., Tao, J., Long, X.D., Fu, G.H., Anti-tumour effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer. Br. J. Pharmacol. 165:1 (2012), 135–147.
234. [234] Liu, C.J., Hwang, J.M., Wu, T.T., Hsieh, Y.H., Wu, C.C., Hsieh, Y.S., Tsai, C.H., Wu, H.C., Huang, C.Y., Liu, J.Y., Anion exchanger inhibitor DIDS induces human poorly-differentiated malignant hepatocellular carcinoma HA22T cell apoptosis. Mol. Cell. Biochem. 308:1–2 (2008), 117–125.
235. [235] Wu, J., Zhang, Y.C., Suo, W.H., Liu, X.B., Shen, W.W., Tian, H., Fu, G.H., Induction of anion exchanger-1 translation and its opposite roles in the carcinogenesis of gastric cancer cells and differentiation of K562 cells. Oncogene 29:13 (2010), 1987–1996.
236. [236] Hwang, J.M., Kao, S.H., Hsieh, Y.H., Li, K.L., Wang, P.H., Hsu, L.S., Liu, J.Y., Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells. Mol. Cell. Biochem. 327:1–2 (2009), 135–144.
237. [237] Webb, B.A., Chimenti, M., Jacobson, M.P., Barber, D.L., Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer 11:9 (2011), 671–677.
238. [238] Ngo, D.C., Ververis, K., Tortorella, S.M., Karagiannis, T.C., Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol. Biol. Rep. 42:4 (2015), 819–823.
239. [239] Izumi, H., Torigoe, T., Ishiguchi, H., Uramoto, H., Yoshida, Y., Tanabe, M., Ise, T., Murakami, T., Yoshida, T., Nomoto, M., Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev. 29:6 (2003), 541–549.
240. [240] Harguindey, S., Arranz, J.L., Wahl, M.L., Orive, G., Reshkin, S.J., Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res. 29:6 (2009), 2127–2136.
241. [241] Izumi, H., Takahashi, M., Uramoto, H., Nakayama, Y., Oyama, T., Wang, K.Y., Sasaguri, Y., Nishizawa, S., Kohno, K., Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 102:5 (2011), 1007–1013.
242. [242] WK CDaR. prognostic and predictive biomarkers in renal cell carcinoma. Tannir, N.M., (eds.) Renal Cell Carcinoma, 2014, Oxford American Oncology Library.
243. [243] Craven, R.A., Banks, R.E., Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice?. Contrib. Nephrol. 160 (2008), 88–106.
244. [244] Brown-Glaberman, U., Marron, M., Chalasani, P., Livingston, R., Iannone, M., Specht, J., Stopeck, A.T., Circulating carbonic anhydrase IX and antiangiogenic therapy in Breast cancer. Dis. Markers, 2016, 2016, 9810383.
245. [245] Kaluz, S., Kaluzova, M., Liao, S.Y., Lerman, M., Stanbridge, E.J., Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?. Biochim. Biophys. Acta 1795:2 (2009), 162–172.
246. [246] Ivanov, S., Liao, S.Y., Ivanova, A., Danilkovitch-Miagkova, A., Tarasova, N., Weirich, G., Merrill, M.J., Proescholdt, M.A., Oldfield, E.H., Lee, J., Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158:3 (2001), 905–919.
247. [247] Huang, W.J., Jeng, Y.M., Lai, H.S., Fong, I.U., Sheu, F.Y., Lai, P.L., Yuan, R.H., Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma. PLoS One, 10(3), 2015, e0119181.
248. [248] Leppilampi, M., Saarnio, J., Karttunen, T.J., Kivela, J., Pastorekova, S., Pastorek, J., Waheed, A., Sly, W.S., Parkkila, S., Carbonic anhydrase isozymes IX and XII in gastric tumors. World J. Gastroenterol. 9:7 (2003), 1398–1403.
249. [249] Chang, H.J., Lee, M.R., Hong, S.H., Yoo, B.C., Shin, Y.K., Jeong, J.Y., Lim, S.B., Choi, H.S., Jeong, S.Y., Park, J.G., Identification of mitochondrial FoF1-ATP synthase involved in liver metastasis of colorectal cancer. Cancer Sci. 98:8 (2007), 1184–1191.
250. [250] Pinheiro, C., Penna, V., Morais-Santos, F., Abrahao-Machado, L.F., Ribeiro, G., Curcelli, E.C., Olivieri, M.V., Morini, S., Valenca, I., Ribeiro, D., Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. J. Transl. Med., 12, 2014, 118.
251. [251] Perut, F., Avnet, S., Fotia, C., Baglio, S.R., Salerno, M., Hosogi, S., Kusuzaki, K., Baldini, N., V-ATPase as an effective therapeutic target for sarcomas. Exp. Cell Res. 320:1 (2014), 21–32.
252. [252] Martinez-Outschoorn, U.E., Whitaker-Menezes, D., Valsecchi, M., Martinez-Cantarin, M.P., Dulau-Florea, A., Gong, J., Howell, A., Flomenberg, N., Pestell, R.G., Wagner, J., Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?. Semin. Oncol. 40:4 (2013), 403–418.
253. [253] Amorim, R., Pinheiro, C., Miranda-Goncalves, V., Pereira, H., Moyer, M.P., Preto, A., Baltazar, F., Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. Cancer Lett. 365:1 (2015), 68–78.
254. [254] Doherty, J.R., Yang, C., Scott, K.E., Cameron, M.D., Fallahi, M., Li, W., Hall, M.A., Amelio, A.L., Mishra, J.K., Li, F., Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 74:3 (2014), 908–920.
255. [255] Rami, M., Dubois, L., Parvathaneni, N.K., Alterio, V., van Kuijk, S.J., Monti, S.M., Lambin, P., De Simone, G., Supuran, C.T., Winum, J.Y., Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J. Med. Chem. 56:21 (2013), 8512–8520.
256. [256] Dubois, L., Peeters, S.G., van Kuijk, S.J., Yaromina, A., Lieuwes, N.G., Saraya, R., Biemans, R., Rami, M., Parvathaneni, N.K., Vullo, D., Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother. Oncol. 108:3 (2013), 523–528.
257. [257] Azzarito, T., Venturi, G., Cesolini, A., Fais, S., Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett. 356:2 Pt B (2015), 697–703.
258. [258] Zheng, Y.T., Yang, H.Y., Li, T., Zhao, B., Shao, T.F., Xiang, X.Q., Cai, W.M., Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol. Sin. 36:5 (2015), 614–626.
259. [259] Hosogi, S., Miyazaki, H., Nakajima, K., Ashihara, E., Niisato, N., Kusuzaki, K., Marunaka, Y., An inhibitor of Na(+)/H(+) exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl(−) concentration via DIDS-sensitive pathways. Cell. Physiol. Biochem. 30:5 (2012), 1241–1253.
260. [260] Nakachi, T., Tabuchi, T., Takasaki, A., Arai, S., Miyazawa, K., Tomoda, A., Anticancer activity of phenoxazines produced by bovine erythrocytes on colon cancer cells. Oncol. Rep. 23:6 (2010), 1517–1522.